Equities analysts expect Radius Health Inc (NASDAQ:RDUS) to report earnings of ($0.82) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Radius Health’s earnings. Radius Health reported earnings of ($1.59) per share in the same quarter last year, which would indicate a positive year over year growth rate of 48.4%. The company is expected to report its next earnings results on Thursday, March 7th.
According to Zacks, analysts expect that Radius Health will report full-year earnings of ($3.79) per share for the current financial year. For the next year, analysts forecast that the company will report earnings of ($2.89) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Radius Health.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($1.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.26) by $0.17. Radius Health had a negative net margin of 346.67% and a negative return on equity of 140.79%. The business had revenue of $27.70 million for the quarter, compared to analyst estimates of $26.00 million. During the same quarter last year, the business earned ($1.31) earnings per share. The business’s revenue for the quarter was up 105.2% on a year-over-year basis.
RDUS has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Radius Health from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Thursday, November 29th. Cowen reiterated a “hold” rating on shares of Radius Health in a research note on Thursday, October 18th. JPMorgan Chase & Co. lowered their price objective on shares of Radius Health from $59.00 to $52.00 and set an “overweight” rating on the stock in a research note on Friday, November 2nd. Finally, BidaskClub upgraded shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. Radius Health has an average rating of “Hold” and a consensus target price of $44.38.
A number of large investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new stake in Radius Health during the third quarter worth approximately $2,542,000. Belpointe Asset Management LLC acquired a new position in Radius Health in the 3rd quarter worth approximately $110,000. Vanguard Group Inc. boosted its stake in Radius Health by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,571,571 shares of the biopharmaceutical company’s stock worth $63,574,000 after purchasing an additional 53,281 shares during the period. Teachers Advisors LLC boosted its stake in Radius Health by 503.7% in the 3rd quarter. Teachers Advisors LLC now owns 446,277 shares of the biopharmaceutical company’s stock worth $7,944,000 after purchasing an additional 372,355 shares during the period. Finally, HealthCor Management L.P. boosted its stake in Radius Health by 77.0% in the 3rd quarter. HealthCor Management L.P. now owns 3,584,580 shares of the biopharmaceutical company’s stock worth $63,806,000 after purchasing an additional 1,559,580 shares during the period.
Shares of NASDAQ RDUS traded down $0.48 during mid-day trading on Friday, reaching $15.84. 746,930 shares of the company traded hands, compared to its average volume of 628,904. Radius Health has a fifty-two week low of $14.52 and a fifty-two week high of $41.16. The company has a debt-to-equity ratio of 1.85, a current ratio of 5.50 and a quick ratio of 5.39. The firm has a market capitalization of $743.21 million, a PE ratio of -2.73 and a beta of 1.06.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.